SAN FRANCISCO — Just days after Amgen announced its $10.4 billion purchase of Onyx Pharmaceuticals, shareholders sued to stop the acquisition, insisting the deal benefits insiders at the expense of ordinary investors.
Plaintiffs lawyers at Robbins Geller Rudman & Dowd and Milberg filed suits this past week seeking to block Amgen from taking over the South San Francisco-based biopharmaceutical company. If approved, the deal would be one of the year's largest healthcare mergers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
